Vir Biotechnology (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 450,342 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) major shareholder Endurance (Cayman) Ltd Svf sold 450,342 shares of the stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $5.56, for a total value of $2,503,901.52. Following the transaction, the insider directly owned 16,233,699 shares in the company, valued at approximately $90,259,366.44. This represents a 2.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

• On Monday, October 6th, Endurance (Cayman) Ltd Svf sold 73,955 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.69, for a total value of $420,803.95.

Vir Biotechnology Stock Up 1.3%

NASDAQ:VIR opened at $5.66 on Wednesday. The company has a market cap of $786.29 million, a PE ratio of -1.42 and a beta of 1.27. Vir Biotechnology, Inc. has a 52 week low of $4.16 and a 52 week high of $14.45. The business’s 50 day moving average is $5.00 and its two-hundred day moving average is $5.31.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.08). The company had revenue of $1.21 million during the quarter, compared to the consensus estimate of $2.38 million. Vir Biotechnology had a negative return on equity of 50.22% and a negative net margin of 2,895.94%.The company’s revenue for the quarter was down 60.5% on a year-over-year basis. During the same period last year, the business posted ($1.02) EPS. As a group, sell-side analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Institutional Trading of Vir Biotechnology

Several large investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. acquired a new position in shares of Vir Biotechnology during the 2nd quarter valued at $35,000. GAMMA Investing LLC increased its position in shares of Vir Biotechnology by 524.3% during the 1st quarter. GAMMA Investing LLC now owns 7,111 shares of the company’s stock valued at $46,000 after purchasing an additional 5,972 shares during the period. Apollon Wealth Management LLC acquired a new position in shares of Vir Biotechnology during the 2nd quarter valued at $50,000. Daiwa Securities Group Inc. increased its position in shares of Vir Biotechnology by 2,200.6% during the 2nd quarter. Daiwa Securities Group Inc. now owns 12,308 shares of the company’s stock valued at $62,000 after purchasing an additional 11,773 shares during the period. Finally, Los Angeles Capital Management LLC acquired a new position in shares of Vir Biotechnology during the 2nd quarter valued at $63,000. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Raymond James Financial assumed coverage on Vir Biotechnology in a report on Friday, July 11th. They issued an “outperform” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Vir Biotechnology in a report on Monday, September 15th. Evercore ISI assumed coverage on Vir Biotechnology in a report on Wednesday, September 3rd. They issued an “outperform” rating and a $12.00 price target on the stock. Bank of America upgraded Vir Biotechnology from a “neutral” rating to a “buy” rating and raised their target price for the company from $12.00 to $14.00 in a research report on Wednesday, August 27th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Vir Biotechnology in a research report on Saturday, September 27th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Vir Biotechnology presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.30.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).